Key facts
- Notable investors include King's College Cambridge, Neo (Consulting Services (B2B)), Odyssey Ventures (London), Perridon Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Axo
- ·The full record, as it builds
Funding rounds
No funding rounds for Axo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axo
Developer of next-generation neural interface technologies intended to restore neurological function and enable novel neural data acquisition. The company's platform integrates advanced bioelectronics that interface seamlessly with biological systems, enabling healthcare providers and researchers to access high-fidelity neural signals and deliver therapeutic outcomes through devices designed to work in harmony with the body's own systems.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2024
- Employees
- 2
- Website
- axoneurotech.com/
- Ownership
- Privately Held (backing)
Axo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axo in its N-PORT filings yet. We sweep new filings monthly.